84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]韓艷,溫利平,劉娜,等.補(bǔ)腎活血方對去卵巢大鼠骨代謝及骨密度的影響[J].中醫(yī)正骨,2015,27(12):7-11.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(補(bǔ)腎活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(12):7-11.
點(diǎn)擊復(fù)制

補(bǔ)腎活血方對去卵巢大鼠骨代謝及骨密度的影響()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第27卷
期數(shù):
2015年12期
頁碼:
7-11
欄目:
基礎(chǔ)研究
出版日期:
2015-12-30

文章信息/Info

Title:
Effect of Bushen Huoxue Fang(補(bǔ)腎活血方)on bone metabolism and bone mineral density in the ovariectomized rats
作者:
韓艷1; 溫利平2; 劉娜3; 陳霖1; 吳春雷1; 吳云剛1
1.溫州醫(yī)科大學(xué)附屬第一醫(yī)院,浙江 溫州 325000;
2.溫州醫(yī)科大學(xué)附屬第二醫(yī)院,浙江 溫州 325027;
3.陜西省西安市紅會醫(yī)院,陜西 西安 710054
Author(s):
HAN Yan1; WEN Liping2; LIU Na3; CHEN Lin1; WU Chunlei1; WU Yungang1
1.The First Affiliated Hospital of Wenzhou Medical University,Wenzhou 325000,Zhejiang,China
2.The Second Affiliated Hospital of Wenzhou Medical University,Wenzhou 325027,Zhejiang,China
3.The Red Cross Hospital of Xi'an City,Xi'an 710054,Shanxi,China
關(guān)鍵詞:
骨質(zhì)疏松; 絕經(jīng)后;  補(bǔ)腎活血方;  骨密度;  骨代謝;  動物實(shí)驗(yàn)
Keywords:
osteoporosis; postmenopausal;  Bushen Huoxue Fang;  bone density;  bone metabolism;  animal experimentation
摘要:
目的:觀察補(bǔ)腎活血方對去卵巢大鼠骨代謝和骨密度的影響。方法:將40只SD雌性大鼠隨機(jī)分成假手術(shù)組、模型組、補(bǔ)腎活血方組和尼爾雌醇組,每組10只。假手術(shù)組行開腹術(shù)但不摘除卵巢,其他3組行雙側(cè)卵巢切除術(shù)。術(shù)后假手術(shù)組和模型組大鼠以蒸餾水灌胃(每次3 mL,每天1次),補(bǔ)腎活血方組大鼠以補(bǔ)腎活血方湯劑灌胃(每次15 g·kg-1,每天1次),尼爾雌醇組大鼠以研細(xì)的尼爾雌醇片和生理鹽水配制成的混懸液灌胃(每次0.6 g·kg-1,每周1次)。灌胃12周后從大鼠心臟取血,離心后吸取上層血清,置入冰箱保存待檢。處死大鼠后,切取右側(cè)股骨中段做標(biāo)本,同時取大鼠腰椎,置入冰箱保存待檢。采用ELISA法測定血清Ⅰ型前膠原氨基端原肽(procollagen type Ⅰ N-terminal propeptide,PINP)、β-膠原降解產(chǎn)物(β isomer of C-terminal telopeptide of typeⅠcollagen,β-CTX)含量,并用雙能X線骨密度測量儀檢測腰椎骨密度。將冰凍切片做HE染色后,在顯微鏡下觀察骨組織病理學(xué)改變。結(jié)果:①血清PINP、β-CTX含量。藥物干預(yù)后各組大鼠血清PINP含量比較,差異有統(tǒng)計學(xué)意義(F=914.448,P=0.000)。組間兩兩比較,假手術(shù)組血清PINP含量低于模型組[(0.109±0.008)μg·mL-1,(0.252±0.006)μg·mL-1,q=-51.807,P=0.000]; 假手術(shù)組血清PINP含量與補(bǔ)腎活血方組[(0.163±0.006)μg·mL-1]、尼爾雌醇組[(0.169±0.005)μg·mL-1]比較,差異均無統(tǒng)計學(xué)意義[q=0.559,P=0.208; q=0.850,P=0.253]; 模型組血清PINP含量高于補(bǔ)腎活血方組和尼爾雌醇組(q=32.248,P=0.000; q=29.957,P=0.000); 補(bǔ)腎活血方組與尼爾雌醇組比較,差異無統(tǒng)計學(xué)意義(q=-0.290,P=0.317)。藥物干預(yù)后各組大鼠血清β-CTX含量比較,差異有統(tǒng)計學(xué)意義(F=963.955,P=0.000)。組間兩兩比較,假手術(shù)組血清β-CTX含量低于模型組[(0.432±0.007)ng·mL-1,(0.766±0.005)ng·mL-1,q=-48.601,P=0.000]; 假手術(shù)組血清β-CTX含量與補(bǔ)腎活血方組[(0.482±0.006)ng·mL-1]、尼爾雌醇組[(0.494±0.008)ng·mL-1]比較,差異均無統(tǒng)計學(xué)意義(q=-0.172,P=0.215; q=0.980,P=0.322); 模型組血清β-CTX含量高于補(bǔ)腎活血方組和尼爾雌醇組(q=41.429,P=0.000; q=39.622,P=0.000); 補(bǔ)腎活血方組血清β-CTX含量與尼爾雌醇組比較,差異無統(tǒng)計學(xué)意義(q=-0.808,P=0.790)。②腰椎骨密度。藥物干預(yù)后各組大鼠腰椎骨密度比較,差異有統(tǒng)計學(xué)意義(F=419.969,P=0.000)。組間兩兩比較,假手術(shù)組腰椎骨密度高于模型組[(0.170±0.004)g·cm-2,(0.097±0.005)g·cm-2,q=35.198,P=0.000]; 假手術(shù)組腰椎骨密度與補(bǔ)腎活血方組[(0.127±0.005)g·cm-2]、尼爾雌醇組[(0.126±0.004)g·cm-2]比較,差異均無統(tǒng)計學(xué)意義(q=2.444,P=0.157; q=1.167,P=0.230); 模型組腰椎骨密度低于補(bǔ)腎活血方組和尼爾雌醇組(q=-14.754,P=0.000; q=-14.031,P=0.000); 補(bǔ)腎活血方組腰椎骨密度與尼爾雌醇組比較,差異無統(tǒng)計學(xué)意義(q=0.723,P=0.474)。③骨組織形態(tài)。假手術(shù)組股骨骨小梁粗壯、飽滿,壁厚,形態(tài)結(jié)構(gòu)完整,排列緊密有序,呈網(wǎng)狀,密度、面積正常,骨小梁間隙較小。模型組股骨骨小梁變細(xì)、變薄,有扭曲或斷裂,骨小梁間隙增大。補(bǔ)腎活血方組和尼爾雌醇組股骨骨小梁較模型組明顯增粗,排列尚整齊并連接成網(wǎng),部分區(qū)域骨小梁間隙略增大。結(jié)論:補(bǔ)腎活血方能降低去卵巢大鼠血清PINP、β-CTX含量,提高骨密度,改善骨組織狀況,但其具體作用機(jī)制尚不明確,有待進(jìn)一步研究。
Abstract:
Objective:To observe the effect of Bushen Huoxue Fang(補(bǔ)腎活血方,BSHXF)on bone metabolism and bone mineral density(BMD)in the ovariectomized rats.Methods:Forty female SD rats were randomly divided into sham-operated group,model group,BSHXF group and nylestriol group,10 cases in each group.The rats in the sham-operated group underwent simple laparotomy while the others underwent bilateral ovariectomy.The rats in the sham-operated group and model group were intragastric administrated with distilled water(3ml at a time,once a day).The rats in BSHXF group were intragastric administrated with BSHXF decoction(15 g/kg at a time,once a day)and the rats in nylestriol group were intragastric administrated with the suspension of nylestriol tablets and normal saline(0.6 g/kg at a time,once a week).After 12-week intragastric administration,the blood samples were obtained from the heart of rats.The upper serum was sucked from the blood samples after centrifuging and was put into the refrigerator for further inspection.The rats were sacrificed and their right middle femurs were fetched out for making specimens and their lumbar vertebraes were fetched out and put into the refrigerator for further inspection.The serum content of procollagen type Ⅰ N-terminal propeptide(PINP)and β isomer of C-terminal telopeptide of typeⅠcollagen(β-CTX)were measured by using enzyme-linked immunosorbent assay(ELISA),and the BMD of lumbar spine were also detected by using dual-energy X-rays BMD radiomete.The pathological changes of bone tissues were observed under the microscope after the frozen sections were received HE staining.Results:There was statistical difference in the serum content of PINP between the 4 groups after the drug intervention(F=914.448,P=0.000).Further pairwise comparison showed that the serum content of PINP of sham-operated group was lower than that of model group(0.109+/-0.008 vs 0.252+/-0.006 μg/mL,q=-51.807,P=0.000).There was no statistical difference in the serum content of PINP between sham-operated group and BSHXF group(0.163+/-0.006 μg/mL)and between sham-operated group and nylestriol group(0.169+/-0.005 μg/mL)(q=0.559,P=0.208; q=0.850,P=0.253).The serum content of PINP was higher in model group compared to BSHXF group and nylestriol group(q=32.248,P=0.000; q=29.957,P=0.000).There was no statistical difference in the serum content of PINP between BSHXF group and nylestriol group(q=-0.290,P=0.317).There was statistical difference in the serum content of β-CTX between the 4 groups after the drug intervention(F=963.955,P=0.000).Further pairwise comparison showed that the serum content of β-CTX of sham-operated group was lower than that of model group(0.432+/-0.007 vs 0.766+/-0.005 ng/mL,q=-48.601,P=0.000).There was no statistical difference in the serum content of β-CTX between sham-operated group and BSHXF group(0.482+/-0.006 ng/mL)and between sham-operated group and nylestriol group(0.494+/-0.008 ng/mL)(q=-0.172,P=0.215; q=0.980,P=0.322).The serum content of β-CTX was higher in model group compared to BSHXF group and nylestriol group(q=41.429,P=0.000; q=39.622,P=0.000).There was no statistical difference in the serum content of β-CTX between BSHXF group and nylestriol group(q=-0.808,P=0.790).There was statistical difference in the BMD of lumbar spine between the 4 groups after the drug intervention(F=419.969,P=0.000).Further pairwise comparison showed that the BMD of lumbar spine of sham-operated group was higher than that of model group(0.170+/-0.004 vs 0.097+/-0.005 g/cm(2),q=35.198,P=0.000).There was no statistical difference in the BMD of lumbar spine between sham-operated group and BSHXF group(0.127+/-0.005 g/cm(2))and between sham-operated group and nylestriol group(0.126+/-0.004 g/cm(2))(q=2.444,P=0.157; q=1.167,P=0.230).The BMD of lumbar spine was lower in model group compared to BSHXF group and nylestriol group(q=-14.754,P=0.000; q=-14.031,P=0.000).There was no statistical difference in the BMD of lumbar spine between BSHXF group and nylestriol group(q=0.723,P=0.474).The femoral bone trabecula in the sham-operated group was thick and arranged tightly,and their morphological structure was complete and cancellous with normal density and area and small interspaces.The femoral bone trabecula in the model group was thin,and some of them were distorted or ruptured with enlarged interspace.The femoral bone trabecula in BSHXF group and nylestriol group were thicker than that of model group and arranged tightly and their trabecular interspace was slightly larger in some regions compared to model group.Conclusion:BSHXF can lower the serum content of PINP and β-CTX and increase the BMD and improve the status of bone tissue in the ovariectomized rats,while its specific mechanism is unclear and need to be further studied.

參考文獻(xiàn)/References:

[1] 胡軍,張華,牟青.骨質(zhì)疏松癥的流行病學(xué)趨勢與防治進(jìn)展[J].臨床薈萃,2011,26(8):729-731.
[2] 李春雯.益氣溫經(jīng)法對絕經(jīng)后骨質(zhì)疏松性髖部骨折患者骨轉(zhuǎn)換指標(biāo)的影響[J].中醫(yī)正骨,2014,26(12):7-9.
[3] 李春雯,劉杰.杭州市骨質(zhì)疏松性髖部骨折的初步調(diào)查[J].中醫(yī)正骨,2013,25(12):42-44.
[4] 喬偉偉,趙先哲.骨質(zhì)疏松動物模型研究進(jìn)展和展望[J].實(shí)驗(yàn)動物與比鉸醫(yī)學(xué),2011,31(1):73-78.
[5] 康軼鑫,李建川,李光磊.單味補(bǔ)腎藥治療骨質(zhì)疏松癥的研究進(jìn)展(一)[J].國際中醫(yī)中藥雜志,2010,32(4):362-365.
[6] 林清,李勁平,栗會敏,等.補(bǔ)骨脂的研究進(jìn)展[J].咸寧學(xué)院學(xué)報(醫(yī)學(xué)版),2012,26(2):175-177.
[7] 陳春,張淑麗.紅花等10種中藥的雌激素活性研究分析[J].中國醫(yī)藥指南,2011,9(14):296-297.
[8] 夏慶華,路千里.熟地黃藥理研究進(jìn)展[J].江西中醫(yī)學(xué)院學(xué)報,2008,20(6):96-97.
[9] Singer FR,Eyre DR.Using biochemical markers of bone turnover in clinical practice[J].Cleve Clin J Med,2008,75(10):739-750.
[10] 施鳴,范璐,陳新.骨代謝標(biāo)志物與骨質(zhì)疏松的相關(guān)性研究[J].標(biāo)記免疫分析與臨床,2012,19(6):351-353.
[11] 闕文君,馮正平.骨轉(zhuǎn)換生化標(biāo)志物的研究進(jìn)展[J].中國骨質(zhì)疏松雜志,2014,20(5):575-579.
[12] Mountzios G,Terpos E,Syrigos K,et al.Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid[J].Transl Res,2010,155(5):247-255.
[13] 俞華威,王兆杰,胡小軍,等.抗骨質(zhì)疏松藥物應(yīng)用的依據(jù):骨生化代謝標(biāo)志物及骨組織病理學(xué)[J].中國組織工程研究,2013,17(28):5126-5132.
[14] Naylor K,Eastell R.Bone turnover markers: use in osteoporosis[J].Nat Rev Rheumatol,2012,8(7):379-389.
[15] Biver E.Use of bone turnover markers in clinical practice[J].Curr Opin Endocrinol Diabetes Obes,2012,19(6):468-473.
[16] 張萌萌,毛未賢,馬倩倩,等.骨代謝標(biāo)志物在骨質(zhì)疏松診療中的應(yīng)用指南(2012年版)(日本骨質(zhì)疏松癥學(xué)會制定)[J].中國骨質(zhì)疏松雜志,2013,19(7):645-657.
[17] Lee J,Vasikaran S.Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis[J].Ann Lab Med,2012,32(2):105-112.

相似文獻(xiàn)/References:

[1]李林軍.應(yīng)用膨脹式椎弓根螺釘內(nèi)固定治療合并骨質(zhì)疏松的 胸腰椎退行性疾病[J].中醫(yī)正骨,2015,27(08):49.
[2]李學(xué)朋,朱立國.骨疏康膠囊對去卵巢大鼠骨小梁的影響[J].中醫(yī)正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康膠囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(12):12.
[3]陳冠軍,陳揚(yáng),莊汝杰.可灌注骨水泥椎弓根螺釘系統(tǒng) 在老年腰椎疾患手術(shù)中的應(yīng)用[J].中醫(yī)正骨,2015,27(02):40.
[4]王丹輝,賁越,韓梅.林蛙油治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2014,26(01):27.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(12):27.
[5]黃建華,黃建武,李慧輝,等.加味左歸丸對絕經(jīng)后骨質(zhì)疏松癥肝腎不足證 患者骨密度的影響[J].中醫(yī)正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(12):19.
[6]項(xiàng)旻,楊虹,林愛菊,等.絕經(jīng)后2型糖尿病患者骨質(zhì)疏松與血微量元素的關(guān)系研究[J].中醫(yī)正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(12):20.
[7]史曉林,李春雯,張志強(qiáng).弱陽離子磁珠分離技術(shù)和基質(zhì)輔助激光解吸電離飛行時間質(zhì)譜技術(shù)在原發(fā)性Ⅰ型骨質(zhì)疏松癥血清標(biāo)志蛋白篩選中的應(yīng)用[J].中醫(yī)正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(12):5.
[8]李明,徐明雄,馮左基,等.自擬壯骨方治療絕經(jīng)后骨質(zhì)疏松癥的療效及作用機(jī)制研究[J].中醫(yī)正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(12):21.
[9]陳俊杰,李晴晴,夏瑢.脂代謝及血清內(nèi)脂素水平與絕經(jīng)后骨質(zhì)疏松癥的 相關(guān)性研究[J].中醫(yī)正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(12):16.
[10]許超,肖魯偉,吳承亮.絕經(jīng)后女性骨質(zhì)疏松癥辨證分型與抑郁焦慮的關(guān)系研究[J].中醫(yī)正骨,2011,23(12):3.
　XU Chao*,XIAO Lu-wei,WU Cheng-liang.*.Study on the relationship between the syndrome differ classification and the depression and anxiety for the postmenopausal women with osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(12):3.
[11]歐國峰,劉鑫,董博,等.絕經(jīng)后骨質(zhì)疏松癥的免疫學(xué)研究進(jìn)展[J].中醫(yī)正骨,2016,28(08):70.
[12]施振宇,劉鐘,陳文亮,等.中醫(yī)綜合療法防治絕經(jīng)后骨量減少的多中心臨床研究[J].中醫(yī)正骨,2017,29(04):1.
　SHI Zhenyu,LIU Zhong,CHEN Wenliang,et al.A multicenter clinical study of complex therapy of traditional Chinese medicine for prevention and treatment of postmenopausal osteopenia[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(12):1.
[13]梁文娜,李西海,李燦東.血清microRNA與絕經(jīng)后骨質(zhì)疏松癥腎虛證的關(guān)系[J].中醫(yī)正骨,2017,29(10):53.
[14]梁文娜,李西海,胡柳,等.二至丸抑制絕經(jīng)后骨質(zhì)疏松大鼠骨代謝紊亂的作用機(jī)制研究[J].中醫(yī)正骨,2017,29(11):1.
　LIANG Wenna,LI Xihai,HU Liu,et al.Study on mechanism of action of Erzhi Wan(二至丸)in inhibiting bone metabolism disorder in rats with postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(12):1.
[15]劉晨,李興勇,姚興璋,等.絕經(jīng)后骨質(zhì)疏松癥的流行病學(xué)概況及發(fā)病機(jī)制研究進(jìn)展[J].中醫(yī)正骨,2018,30(03):52.
[16]楊依然,劉鐘,毛一凡,等.酪蛋白激酶-2相互作用蛋白1基于磷脂酰肌醇3-激酶/蛋白激酶B/哺乳動物雷帕霉素靶蛋白通路參與絕經(jīng)后骨質(zhì)疏松癥發(fā)生發(fā)展過程中細(xì)胞自噬的機(jī)制[J].中醫(yī)正骨,2018,30(04):59.
[17]曹俊青,鄭劍南,張麟.右歸丸聯(lián)合阿侖膦酸鈉口服治療絕經(jīng)后骨質(zhì)疏松癥腎陽虛證的臨床研究[J].中醫(yī)正骨,2018,30(05):20.
　CAO Junqing,ZHENG Jiannan,ZHANG Lin.A clinical study of oral application of Yougui Wan(右歸丸)and alendronate sodium for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(12):20.
[18]李中萬,徐紹俊,楊廣鋼,等.健腎方聯(lián)合碳酸鈣D3咀嚼片(Ⅱ) 治療絕經(jīng)后骨質(zhì)疏松癥腎陽虛證[J].中醫(yī)正骨,2018,30(08):11.
　LI Zhongwan,XU Shaojun,YANG Guanggang,et al.Oral application of Jianshen Fang(健腎方)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(12):11.
[19]趙凡,劉全,吳連國.口服強(qiáng)骨飲聯(lián)合碳酸鈣D3片治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2019,31(04):26.
　ZHAO Fan,LIU Quan,WU Lianguo.Oral applications of Qianggu Yin(強(qiáng)骨飲)and calcium carbonate and Vitamin D3 tablets for treatment of postmenopausal osteoporosis:a clinical study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(12):26.
[20]史曉林,楊依然,劉鐘,等.基于蛋白質(zhì)組學(xué)方法分析絕經(jīng)后骨質(zhì)疏松癥全血差異蛋白[J].中醫(yī)正骨,2019,31(06):7.
　SHI Xiaolin,YANG Yiran,LIU Zhong,et al.Analysis of proteins which are differentially expressed in whole blood of patients with postmenopausal osteoporosis using proteomics approach[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(12):7.

備注/Memo

備注/Memo:
2015-10-22收稿 2015-11-18修回
基金項(xiàng)目:浙江省溫州市2014年第一期科技計劃項(xiàng)目(Y20140013)
更新日期/Last Update: 2015-12-30